● enhanced sanctions and penalties for addressing non-compliant advertising
● an amended Therapeutic Goods Advertising Code from 1 July 2018
● a streamlined complaints handling system from 1 July 2018
● the abolishment of the requirement for certain advertisements to be pre-approved from1 July 2020, allowing for a transition period.
In addition a formal education program including guidance materials will be developed and implemented to support advertisers.
These changes reflect the recommendations of the Review of Medicines and Medical Devices Regulation (the Review) on reforms to the advertising framework for therapeutic goods.
Further information on each change and expected timeframes can be found at: Reforms to the therapeutic goods advertising framework.
More Information On TGA